<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-291" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anabolic Steroid Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Middlebrook</surname>
            <given-names>Igor</given-names>
          </name>
          <aff>Central Michigan University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schoener</surname>
            <given-names>Benjamin</given-names>
          </name>
          <aff>Central Michigan University COM</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Igor Middlebrook declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Schoener declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-291.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Anabolic steroids such as testosterone are produced naturally and enhance protein synthesis at the cellular level. There are also synthetic analogs available that have been widely misused as performance-enhancing drugs. This activity outlines the mechanism of action, adverse effects, and toxicity of anabolic steroids and the role of the interprofessional team in caring for patients with anabolic steroid toxicity or patients that misuse these agents.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of anabolic steroids.</p></list-item><list-item><p>Describe the epidemiology surrounding the misuse of anabolic steroids.</p></list-item><list-item><p>Identify the clinical manifestations of anabolic steroid toxicity.</p></list-item><list-item><p>Describe interprofessional team strategies to improve outcomes in patients with anabolic steroid toxicity or patients that misuse these agents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=291">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-291.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Androgenic-anabolic steroids (AAS) are widely missed worldwide as performance-enhancing agents. The use of AAS started in competitive sports and spread to non-competitive athletes. The World Anti-Doping Agency banned AAS in&#x000a0;the 1950s and has continued adding new methods and new variations of AAS. Currently, the Centers for Disease Control and Prevention estimates that the majority of AAS users are adolescent males.<xref ref-type="bibr" rid="article-291.r1">[1]</xref>&#x000a0;The hypothalamus is the integrating center for the reproductive axis (HPG). It receives signals from the amygdala, olfactory, and visual cortex. Gonadotropin-releasing hormone (GnRH) then gets released into a venous portal system that carries it to the adenohypophysis of the pituitary gland. In addition to signals from the central nervous system, humoral factors from the testes also play a role in modulating the release of GnRH. Gonadotropin-releasing hormone release is pulsatile, seasonal, and circadian. Levels of GnRH are highest during spring and in the morning, with peaks occurring every 90 to 120 minutes. Once released, GnRH acts on the pituitary gland and promotes the production and release of luteinizing hormone (LH) and, to a lesser extent, follicle-stimulating hormone (FSH). Luteinizing hormone, in turn, acts on Leydig cells in the testes, which are the site of production of most of the endogenous androgens. Androgen production also occurs in the adrenal cortex, and the conversion of androstenedione peripherally. Testosterone, in turn, inhibits the production of GnRH in the hypothalamus.</p>
        <p>Testosterone is a 19-carbon steroid and is the most potent endogenous androgen. As such, it is the basis of most AAS. The addition of various functional groups to this basic 19-carbon structure&#x000a0;changes the androgenic, anabolic, and toxicity profiles of AAS. Testosterone and other AAS act to increase muscle hypertrophy through modulating androgen receptors and their interaction with co-activators. It also increased muscle hypertrophy through modulation of receptor expression through intercellular metabolism, an anti-catabolic effect, by interfering with glucocorticoid receptor expression and various genomic and non-genomic pathways that act on the central nervous system.<xref ref-type="bibr" rid="article-291.r2">[2]</xref></p>
        <p>Studies of long-term AAS users showed an increase in muscle fiber hypertrophy. Both type I and type II had significant hypertrophy. Even though type II muscle fibers compose most muscle mass in power-lifters, it was type I fibers that enlarged the most, with a 33% increase in size. Additionally, type&#x000a0;II fibers require a lesser dose of testosterone 300 mg vs. 600 mg for type I to exhibit hypertrophy.<xref ref-type="bibr" rid="article-291.r3">[3]</xref>&#x000a0;One of the critical mechanisms by which AAS induces muscle hypertrophy is by increasing the synthesis of contractile proteins. Injections (IM) of 200 mg of testosterone enanthate increased synthesis two-fold by increasing the rate at which amino acids underwent reuse, while the protein turnover rate was unchanged. Each muscle fiber contains multiple myonuclei that can support a certain level of protein synthesis. With resistance training, these myonuclei increase in size and can support an increase in protein synthesis and the cross-sectional area of a muscle fiber. On average, this increase is no more than 26% for type II muscle fiber, which is termed &#x0201c;ceiling theory,&#x0201d; however, with AAS supplementation, researchers observed a significant increase of 36%.<xref ref-type="bibr" rid="article-291.r4">[4]</xref> This effect is even higher for type I muscle fibers.</p>
        <p>Short-term administration of androgenic-anabolic steroids (300 mg per week for 20 weeks) increases the number of muscle satellite cells; this is thought to be because testosterone promotes satellite cell proliferation and entry into the cell cycle. As these cells enter the cell cycle, some daughter cells do not differentiate and become quiescent cells. Other satellite cells, while dividing, may become new myonuclei or proceed to form new myotubules.<xref ref-type="bibr" rid="article-291.r3">[3]</xref>&#x000a0;While the exact mechanism remains unclear, murine models showed that testosterone-treated C3H 10T1/2 pluripotent mesenchymal cells showed increases in MyoD and myosin-heavy chains. Testosterone supplementation is a potent regulator of lipolysis that influences catecholamine signal transduction. Testosterone also inhibits adipocyte precursor cells from differentiation.<xref ref-type="bibr" rid="article-291.r5">[5]</xref>&#x000a0;Finally, there may be an androgen receptor-independent pathway through which testosterone may act. AAS may work on G-protein coupled receptors at the plasma membrane, which would increase Ca2+ concentration and activate ERK1/2 kinases, which then would phosphorylate transcription factors.</p>
      </sec>
      <sec id="article-291.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Androgenic-anabolic steroids are mainly used for their effects on athletic performance and muscle size. An increase in muscle mass and strength was seen after administration of testosterone for 6 weeks in young, healthy males, averaging 19 years old.<xref ref-type="bibr" rid="article-291.r6">[6]</xref> Similar effects were observed after administering 600 mg testosterone per week to trained and untrained men for ten weeks. Interestingly, men who&#x000a0;did not participate in resistance training also gained muscle mass, albeit at a slower rate than those with resistance training and testosterone supplementation.<xref ref-type="bibr" rid="article-291.r7">[7]</xref>&#x000a0;The effects of testosterone supplementation have shown to be dose-dependent and associated with changes in muscle pennation angle. Fascicle length and muscle pennation angle increase is needed to increase muscle surface area and the subsequent rise of the force of contraction.<xref ref-type="bibr" rid="article-291.r8">[8]</xref></p>
        <p>Interestingly, low levels of testosterone in geriatric males correlate with an increased risk of atrial fibrillation (AF).<xref ref-type="bibr" rid="article-291.r9">[9]</xref> Low levels of testosterone also correlate to coronary artery disease. However, it is not clear whether coronary artery disease (CAD) preceded low testosterone levels or followed; this is an inverse relationship between CAD and testosterone levels, suggesting that testosterone supplementation may decrease the severity of CAD. A similar relationship exists between mortality associated with CAD and the level of testosterone. Testosterone has been used to treat angina since the 1930s. Multiple studies since then confirmed a significant reduction in angina, the frequency of attacks, and the increase in angina-free periods. There is also a long-established association between type 2 diabetes mellitus (T2DM) and low testosterone. Recent studies have shown that not only total testosterone but also free testosterone and DHT levels also decrease in T2DM.</p>
        <p>Additionally, studies have demonstrated that testosterone supplementation decreases the risk of developing T2DM. &#x000a0;Testosterone increases metabolism and lipolysis. Evidence from multiple cohort studies shows that reduced levels of testosterone are seen in patients with obesity. Testosterone supplementation of 3 intramuscular injections significantly decreased the patient&#x02019;s BMI by 1.3 in 30 weeks. Data on testosterone's effect on lipid balance is conflicted and needs to be studied further. Testosterone supplementation, however, has been shown to decrease prolonged QT and ST intervals, often seen with aging and Cushing disease.</p>
        <p>Patients with congestive heart failure (CHF) due to activation of endocrine and inflammatory pathways also have low testosterone levels. Decreasing testosterone levels have been recently shown to be associated with progressive worsening of CHF. Administration of testosterone to CHF patients, however, did not change the left ventricular ejection fraction. Levels of total testosterone and free testosterone remain predictors of CHF. Testosterone has also been shown to be effective in increasing exercise tolerance in a patient with CHF and chronic obstructive pulmonary disease (COPD). Testosterone supplementation improved the 6-minute walk distance in patients with COPD. It is likely that testosterone causes the skeletal muscle to have more Type I fibers, thus increasing exercise tolerance.<xref ref-type="bibr" rid="article-291.r10">[10]</xref>&#x000a0;Low levels of testosterone correlate with chronic liver disease (CLD). Up to 90% of males considered for a liver transplant show marked a reduction in free testosterone. The severity of CLD has an inverse correlation to testosterone levels. Mortality secondary to CLD was also inversely tied to free testosterone levels. An 8% increase in mortality is associated with a 1 nmol/L drop of free testosterone.<xref ref-type="bibr" rid="article-291.r11">[11]</xref></p>
      </sec>
      <sec id="article-291.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Conservative estimates are that around 1 to 3 million people misuse AAS in the United States. This number is on the rise as more adolescents report using AAS as early as high school, and there is an even higher prevalence in weight lifters, bodybuilders, military, law enforcement, and prison populations.<xref ref-type="bibr" rid="article-291.r12">[12]</xref> A meta-analysis of 187 studies in 2014 showed the use of AAS worldwide had become a serious public health problem. The lifetime prevalence of the use of AAS is higher in men (6.4%) than women (1.6%).<xref ref-type="bibr" rid="article-291.r13">[13]</xref></p>
      </sec>
      <sec id="article-291.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There are many androgen receptors in the brain; thus, there are many neural and behavioral effects associated with AAS misuse. Side effects include hyperexcitability, suicidal tendencies, and aggressive behavior. Neurotoxicity-induced apoptosis of neuronal cells was comparable to features of Alzheimer disease and Huntington disease. Researchers observed increased levels of beta-amyloid in individuals with a lengthy history of AAS misuse. Murine models demonstrated that excitotoxic neuronal death, induced by N-methyl-d-aspartate (NMDA), underwent amplification in the presence of testosterone.<xref ref-type="bibr" rid="article-291.r14">[14]</xref> Methandienone and 17-alpha-methyltestosterone were shown to inhibit neurite networks, induce apoptosis in AR-expressing neurons, and modulate levels of apoptosis-related proteins ERK and caspase-3.<xref ref-type="bibr" rid="article-291.r15">[15]</xref> This evidence prompted a more in-depth look at the effects of androgenic-anabolic steroids on cognition and memory. Self-reported AAS users received five computerized tests of cognitive performance: paired associates learning, rapid visual information processing, choice reaction test, verbal recognition memory, and pattern recognition memory. There was no significant performance difference between AAS users and nonusers in terms of&#x000a0;sustained attention, response speed, and verbal memory. However, pattern recognition memory and performance testing showed a marked decrease of almost one standard deviation in scores of AAS users vs non-users.<xref ref-type="bibr" rid="article-291.r16">[16]</xref></p>
        <p>Gingival fibroblasts contain a significant number of androgenic receptors. Testosterone converts to DHT in peripheral tissues such as gingival tissues; this is especially evident if the tissue is inflamed, as the number of ARs and amount of DHT rises. Wound healing positively correlates to systemic sex hormones. Young males with above-average amounts of testosterone showed impaired wound healing, whereas elderly females with low amounts of free testosterone in the blood showed improved wound healing. A study of 42 AAS users and 50 nonuser controls was performed to see how AAS affects periodontal health. Both participant groups were 19 to 40 years old. Periodontitis was present in a more significant percentage of AAS users (32%) vs. controls (16.7%). Dental plaque was also present more frequently in AAS users than controls. Clinical attachment loss was seen almost 2.4 times more often in AAS users than in control nonusers. Researchers also examined the microbiota in AAS users vs. controls. Infection with <italic toggle="yes">P. intermedia</italic> was 4.9 times more likely in AAS users vs non-users. Similarly, AAS users were 3.5 times more likely to be infected with <italic toggle="yes">A actinomycetemcomitans</italic> than the control group. Finally, fungal cultures showed that AAS users were more likely to have <italic toggle="yes">Candida</italic> pocketing than nonusers.<xref ref-type="bibr" rid="article-291.r17">[17]</xref></p>
      </sec>
      <sec id="article-291.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Myocyte histopathological changes include testosterone and other AAS-induced reactive oxygen species (ROS) generation. They, in turn, induce cell apoptosis. Testosterone also increased Bax (apoptosis promoter) to Bcl-2 (apoptosis inhibitor) ratio.<xref ref-type="bibr" rid="article-291.r18">[18]</xref></p>
      </sec>
      <sec id="article-291.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Cardiovascular Signs of Anabolic Steroid Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension secondary to elevated systemic vascular resistance&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypercoagulative state may result in intracardiac thromboses, venous thromboses</p>
          </list-item>
          <list-item>
            <p>Direct myocardial toxicity and pro-inflammatory biomarker profile, which may result in non-ischemic cardiomyopathy, myocardial&#x000a0;infarction, heart failure</p>
          </list-item>
          <list-item>
            <p>Dyslipidemia</p>
          </list-item>
          <list-item>
            <p>Erythrocythemia</p>
          </list-item>
          <list-item>
            <p>Accelerated coronary atherosclerosis&#x000a0;<xref ref-type="bibr" rid="article-291.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hepatic System Signs of Anabolic Steroid Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cholestasis</p>
          </list-item>
          <list-item>
            <p>Nonalcoholic steatohepatitis (NASH)</p>
          </list-item>
          <list-item>
            <p>Direct liver toxicity</p>
          </list-item>
          <list-item>
            <p>Hepatic neoplasms</p>
          </list-item>
          <list-item>
            <p>Decreased SHBG</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly</p>
          </list-item>
          <list-item>
            <p>Bile acid nephropathy&#x000a0;<xref ref-type="bibr" rid="article-291.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Endocrine System Signs of Anabolic Steroid Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acne</p>
          </list-item>
          <list-item>
            <p>Gynecomastia (males)</p>
          </list-item>
          <list-item>
            <p>Virilization (females)</p>
          </list-item>
          <list-item>
            <p>Irregular menses (females)</p>
          </list-item>
          <list-item>
            <p>Hypogonadism</p>
          </list-item>
          <list-item>
            <p>Decreased levels of HDL</p>
          </list-item>
          <list-item>
            <p>Premature epiphyseal closure</p>
          </list-item>
        </list>
        <p>
<bold>Neuropsychiatric Symptoms of Anabolic Steroid Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Major depression</p>
          </list-item>
          <list-item>
            <p>Body dysmorphic syndrome</p>
          </list-item>
          <list-item>
            <p>Narcissistic personality disorder</p>
          </list-item>
          <list-item>
            <p>Aggression</p>
          </list-item>
          <list-item>
            <p>Dependence</p>
          </list-item>
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Bipolar depressive disorder</p>
          </list-item>
          <list-item>
            <p>Suicidal tendencies</p>
          </list-item>
          <list-item>
            <p>Decreased pattern recognition</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-291.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation begins with a thorough patient history and a physical exam. It is essential to establish a temporal relationship between a chief complaint, presenting symptoms, and the use of the anabolic steroid. It is equally important to determine which specific agent is in use, as that information can aid the clinician in obtaining the proper workup. Laboratory testing remains a challenge for clinicians as there are over 170 variants of anabolic steroids and no single rapid test to identify every agent. However, even when there is a high suspicion of the presence of a specific agent, confirmatory analysis is generally gas chromatography. Testing may take a considerable amount of time, depending on the institutional capabilities.</p>
      </sec>
      <sec id="article-291.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Initial treatment of suspected acute anabolic steroid toxicity starts with discontinuing the offending agent, followed by largely supportive measures while awaiting the results of the diagnostic workup. The provider should tailor further treatment to the underlying pathology caused by the&#x000a0;anabolic steroid use, as signs of toxicity may manifest in multiple organ systems. Multivitamins consisting mostly of vitamins B1, B6, B12, nicotinamide, and linoleic acid have been shown to protect hepatocytes from AAS-induced toxicity.<xref ref-type="bibr" rid="article-291.r21">[21]</xref></p>
      </sec>
      <sec id="article-291.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for anabolic steroid toxicity are broad, as AASs affect many organ systems.</p>
        <list list-type="bullet">
          <list-item>
            <p>Adrenal neoplasm</p>
          </list-item>
          <list-item>
            <p>Anorexia</p>
          </list-item>
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
          <list-item>
            <p>Conn syndrome</p>
          </list-item>
          <list-item>
            <p>Drug-induced hirsutism</p>
          </list-item>
          <list-item>
            <p>Drug-induced jaundice</p>
          </list-item>
          <list-item>
            <p>Hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>Hepatic malignancy</p>
          </list-item>
          <list-item>
            <p>Hepatitis</p>
          </list-item>
          <list-item>
            <p>Ovarian cancer</p>
          </list-item>
          <list-item>
            <p>Precocious puberty</p>
          </list-item>
          <list-item>
            <p>Thromboembolic state</p>
          </list-item>
          <list-item>
            <p>Vasculopathy</p>
          </list-item>
          <list-item>
            <p>Viral myocarditis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-291.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Spermatogenesis is stimulated by LH and follicle-stimulating hormone (FSH) release from the anterior pituitary and inhibited by the negative feedback of testosterone and inhibin. AAS mimics testosterone, which creates an increase of inhibition of spermatogenesis and a marked decrease in levels of LH and FSH. Male androgenic-anabolic steroid users show severe to moderate oligozoospermia 5-20x106/mL. The percentage of motile sperm is also significantly impaired in AAS users. Those users who stopped taking AAS for more than four months showed sperm levels return to normal, even after years of taking AAS.<xref ref-type="bibr" rid="article-291.r22">[22]</xref> Gynecomastia is another often reported side-effect of AAS misuse. Gynecomastia is a benign proliferation of breast tissue driven by the increased estrogen receptor expression secondary to alteration in hypothalamic-pituitary axis (HPA) axis function. Estradiol nuclear and cellular receptor concentrations were similarly elevated in AAS users with pre-malignant soft tissue proliferation of the breast and patients with benign breast tissue proliferation, not due to AAS use.<xref ref-type="bibr" rid="article-291.r23">[23]</xref> The only definitive way to treat gynecomastia is the cessation of steroid use and surgical excision.</p>
      </sec>
      <sec id="article-291.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of anabolic steroid toxicity include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Depression may persist for years</p>
          </list-item>
          <list-item>
            <p>Gynecomastia may require surgical excision</p>
          </list-item>
          <list-item>
            <p>Hirsutism may be irreversible</p>
          </list-item>
          <list-item>
            <p>Hepatic tumors</p>
          </list-item>
          <list-item>
            <p>If the route of administration is intramuscular, there is a risk of contracting human immunodeficiency virus or hepatitis C virus</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-291.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Various public safety campaigns exist to educate aspiring athletes about the dangers of using anabolic steroids. Most major sports associations continuously test their athletes for banned substances, which include AAS. It is essential to acknowledge that testing will never catch up to cover every single anabolic compound, but new compounds are regularly added to the list of banned substances. Primary care physicians should suspect AAS misuse if any of the following are present:</p>
        <list list-type="bullet">
          <list-item>
            <p>Participation in sports in which an increase in physical strength, speed, and agility is advantageous</p>
          </list-item>
          <list-item>
            <p>Males</p>
          </list-item>
          <list-item>
            <p>Increased musculature or accelerated rate of muscle gain</p>
          </list-item>
          <list-item>
            <p>Increase in acne</p>
          </list-item>
          <list-item>
            <p>Oligospermia</p>
          </list-item>
          <list-item>
            <p>Gynecomastia</p>
          </list-item>
          <list-item>
            <p>Early puberty</p>
          </list-item>
          <list-item>
            <p>High hematocrit</p>
          </list-item>
          <list-item>
            <p>Hirsutism in females</p>
          </list-item>
        </list>
        <p>Clinicians should educate the patients regarding the use of AAS and advise them that possession of AAS is a criminal offense as well as a violation of anti-doping rules of most sports organizations.</p>
      </sec>
      <sec id="article-291.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Androgen abuse is a very common problem among athletes. While most sporting organizations conduct random screening checks, newer analogs are introduced every year; hence, discovering people who abuse these agents is not always easy. Various public safety campaigns exist to educate aspiring athletes about the dangers of using anabolic steroids. Most major sports associations continuously test their athletes for banned substances, which include AAS. In fact, many sporting organizations now employ clinicians, including physicians and nurses, to educate athletes about the harms of androgen abuse.</p>
        <p>A 5-year study funded by WADA (World Anti-Doping Agency) published in 2016 highlighted the strategy to reduce AAS misuse. The results of the study were predictable in that the areas of focus should be on prevention and education. Coaches, athletic trainers, and team physicians are not appropriately trained to identify athletes at risk. WADA has multiple educational programs and many resources available on its website for each discipline. Prevention is the best strategy to reduce AAS misuse and sequelae resulting from it. WADA maintains that each athlete is responsible for every chemical in their body. Sports organizations can issue severe penalties if they find any of the banned substances. Physicians and nurse practitioners treating athletes need to be aware of medical exception rules available on WADA's website. Most importantly, clinicians should be mindful of the risk factors for AAS misuse, clinical presentations, complications of use, and other conditions that may mimic AAS misuse.</p>
        <p>In summary, AAS misuse and toxicity requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. The nurses often assist with patient education and report to the clinical team individuals they believe are at risk. Pharmacists trained in toxicology may assist the interprofessional team in managing patients who&#x000a0;have untoward complications. The pharmacist can also assist in drug reconciliation and assist the team in avoiding drug interaction. Coaches and athletic trainers should be included in addressing the dangers of androgen use and be taught to identify potentially concerning athletes.&#x000a0;</p>
      </sec>
      <sec id="article-291.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=291&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=291">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/anabolic-steroid-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=291">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/291/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=291">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-291.s16">
        <title>References</title>
        <ref id="article-291.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parkinson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Anabolic androgenic steroids: a survey of 500 users.</article-title>
            <source>Med Sci Sports Exerc</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>644</fpage>
            <page-range>644-51</page-range>
            <pub-id pub-id-type="pmid">16679978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kicman</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of anabolic steroids.</article-title>
            <source>Br J Pharmacol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>154</volume>
            <issue>3</issue>
            <fpage>502</fpage>
            <page-range>502-21</page-range>
            <pub-id pub-id-type="pmid">18500378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement.</article-title>
            <source>Br J Pharmacol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>154</volume>
            <issue>3</issue>
            <fpage>522</fpage>
            <page-range>522-8</page-range>
            <pub-id pub-id-type="pmid">18414389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolfe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferrando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheffield-Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Testosterone and muscle protein metabolism.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>75 Suppl</volume>
            <fpage>S55</fpage>
            <page-range>S55-9; discussion S59-60</page-range>
            <pub-id pub-id-type="pmid">10959218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Artaza</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Gonzalez-Cadavid</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.</article-title>
            <source>Endocrinology</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>144</volume>
            <issue>11</issue>
            <fpage>5081</fpage>
            <page-range>5081-8</page-range>
            <pub-id pub-id-type="pmid">12960001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedl</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dettori</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hannan</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Patience</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Plymate</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men.</article-title>
            <source>J Steroid Biochem Mol Biol</source>
            <year>1991</year>
            <volume>40</volume>
            <issue>4-6</issue>
            <fpage>607</fpage>
            <page-range>607-12</page-range>
            <pub-id pub-id-type="pmid">1958561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tricker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Casaburi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Storer</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Clevenger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shirazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhasin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men--a clinical research center study.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>81</volume>
            <issue>10</issue>
            <fpage>3754</fpage>
            <page-range>3754-8</page-range>
            <pub-id pub-id-type="pmid">8855834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blazevich</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Giorgi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of testosterone administration and weight training on muscle architecture.</article-title>
            <source>Med Sci Sports Exerc</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1688</fpage>
            <page-range>1688-93</page-range>
            <pub-id pub-id-type="pmid">11581553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magnani</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Murabito</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Vasan</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Coviello</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study.</article-title>
            <source>Circ Arrhythm Electrophysiol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-12</page-range>
            <pub-id pub-id-type="pmid">24610804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oskui</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Herring</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mayeda</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Burstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kloner</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Testosterone and the cardiovascular system: a comprehensive review of the clinical literature.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2013</year>
            <month>Nov</month>
            <day>15</day>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>e000272</fpage>
            <pub-id pub-id-type="pmid">24242682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinclair</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angus</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Grossmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gow</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Muscle mass and mortality in chronic liver disease: the impact of testosterone.</article-title>
            <source>Liver Transpl</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>504</fpage>
            <page-range>504-5</page-range>
            <pub-id pub-id-type="pmid">24357579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sj&#x000f6;qvist</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rane</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Use of doping agents, particularly anabolic steroids, in sports and society.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>May</month>
            <day>31</day>
            <volume>371</volume>
            <issue>9627</issue>
            <fpage>1872</fpage>
            <page-range>1872-82</page-range>
            <pub-id pub-id-type="pmid">18514731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sagoe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andreassen</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Torsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pallesen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis.</article-title>
            <source>Ann Epidemiol</source>
            <year>2014</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>383</fpage>
            <page-range>383-98</page-range>
            <pub-id pub-id-type="pmid">24582699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pistar&#x000e0;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Corsaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomasello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giuffrida</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sortino</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nicoletti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Copani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neurotoxic properties of the anabolic androgenic steroids nandrolone and methandrostenolone in primary neuronal cultures.</article-title>
            <source>J Neurosci Res</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>592</fpage>
            <page-range>592-600</page-range>
            <pub-id pub-id-type="pmid">21290409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basile</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Binmadi</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Paoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Proia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Supraphysiological doses of performance enhancing anabolic-androgenic steroids exert direct toxic effects on neuron-like cells.</article-title>
            <source>Front Cell Neurosci</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>69</fpage>
            <pub-id pub-id-type="pmid">23675320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kean</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Cognitive deficits in long-term anabolic-androgenic steroid users.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2013</year>
            <month>Jun</month>
            <day>01</day>
            <volume>130</volume>
            <issue>1-3</issue>
            <fpage>208</fpage>
            <page-range>208-14</page-range>
            <pub-id pub-id-type="pmid">23253252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brusca</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Verdugo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Amighini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Albaina</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Moragues</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Anabolic steroids affect human periodontal health and microbiota.</article-title>
            <source>Clin Oral Investig</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>1579</fpage>
            <page-range>1579-86</page-range>
            <pub-id pub-id-type="pmid">24221579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Pestana</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Queiroz</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zanotto</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Chignalia</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Valim</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Curti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tostes</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Testosterone induces apoptosis in vascular smooth muscle cells via extrinsic apoptotic pathway with mitochondria-generated reactive oxygen species involvement.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>306</volume>
            <issue>11</issue>
            <fpage>H1485</fpage>
            <page-range>H1485-94</page-range>
            <pub-id pub-id-type="pmid">24658017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baggish</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Kanayama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>May</month>
            <day>23</day>
            <volume>135</volume>
            <issue>21</issue>
            <fpage>1991</fpage>
            <page-range>1991-2002</page-range>
            <pub-id pub-id-type="pmid">28533317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luciano</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Castano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moeckel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Bile acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-6</page-range>
            <pub-id pub-id-type="pmid">24953892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pagonis</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Koukoulis</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Hadjichristodoulou</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Toli</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Angelopoulos</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Multivitamins and phospholipids complex protects the hepatic cells from androgenic-anabolic-steroids-induced toxicity.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-66</page-range>
            <pub-id pub-id-type="pmid">17852158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knuth</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Maniera</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nieschlag</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Anabolic steroids and semen parameters in bodybuilders.</article-title>
            <source>Fertil Steril</source>
            <year>1989</year>
            <month>Dec</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>1041</fpage>
            <page-range>1041-7</page-range>
            <pub-id pub-id-type="pmid">2512180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-291.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salazar</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hyperplastic changes and receptor status in the breast tissue of bodybuilders under anabolic-androgenic steroid stimulation.</article-title>
            <source>Arch Androl</source>
            <year>2000</year>
            <season>Jul-Aug</season>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">10959495</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
